康龍化成(03759.HK)擬聯手康君投資設立生物醫藥基金
格隆匯1月20日丨康龍化成(03759.HK)公佈,於2020年1月20日,公司與康君投資訂立有關基金設立及投資的有限合夥協議。基金將於中國以有限合夥企業方式註冊成立,其主要目標為(其中包括)對生物醫藥相關的企業或實體進行股權及╱或可轉債投資。
於公告日期,康君投資由寧波康灣、公司及君聯資本各持其40%、30%及30%的股權。寧波泓灣持有寧波康灣75%的股權,而寧波泓灣由公司董事樓小強及鄭北共同持有。因此,寧波康灣為董事聯繫人的附屬公司。君聯資本為公司主要股東,並持有康君投資30%的股權,因此康君投資為主要股東的聯繫人。
董事會認為,基金投資為公司創造了一個契機,有助公司促進其在新藥研發及其他相關服務領域的戰略發展、提升其競爭力及鞏固其市場地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.